- Email: [email protected]
Gènes codant pour des iota-carraghénanes et leur utilisation pour la production d'enzymes de biodégradation des carraghénanes (T Barbeyron et al, FR)
diovascular disease (G Neufeld et ai, IL) Technion Research et Development and Collateral Therapeutics W WO 98/10071, PCT. The present invention relates to a novel VEGF protein product, and nucleic acid encoding the novel protein product, comprising exons 1-6 and 8 of the VEGF gene, and its use thereof in treating the cardiovascular system and its diseases through effects on anatomy, conduit fonction, and permeability. (... )
Maladie neurodegenerative > Compositions and methods for treatment of neurological disorders and neurodegenerative diseases (RK Lee and RJ Wurtman, US) Massachusetts Institute of Technology N" WO 98/09523, PCT. It has been discovered that the stimulation of IS-adrenergic receptors, which activate cAMP formation, give rise to increase APP and GFAP synthesis in astrocytes. Hence, the in vitro or in uiuo exposure of neuronal cells to certain compositions comprising IS-adrenergic receptor ligands or agonists, including eg, norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. (...) > Neurological disease
model ( PH van der Putten, CH) Novartis AG and the inventor N° WO 98/11242, PCT. There is provided the use of a metabotropic glutamate receptor mGluR7 agonist for the facilitation of neurotransmitter release from a nerve ending and the treatment of neurological conditions, including epilepsy. Moreover, the invention provides transgenic knockout non-human mammals lacking the mGluR7 gene, suitable for studying mGluR 7 and modulators thereof as well as epilepsy.
Therapies genique
et cellulaire
> Human satelite microchromosomes as vectors for gene therapy (J Xia, CN) Human Medical University N" 838526, EP.
The present invention provides novel eukaryotic expression vectors which can accommodate large polynucleotides, such as polynucleotides encoding genes. The vectors of this invention can be stably maintained and autonomously replicated as extrachromosomal elements in eukaryotic cells, particulary, mammalian, and more particularly human, for use in somatic gene rhera py. (... )
Systeme de delivrance > Compositions and me-
thods for delivery of nucleic acids to hepatocytes (OLJarvis and R Landford, US) The Texas A and M University System and the inventors N" WO 98/06855, PCT. Disclosed are recombinant baculoviruses that are used to deliver hepatocyte expressable nucleic acid constructs specifically to heparocyres. Also provided are a variety of recombinant baculovi;us vectors which comprise at least one oligosaccharide processing enzyme gene and a hepatocyte expressible nucleic acid segment. The invention also provides methods of using the expression systems and recombinant baculoviruses, particularly in the treatment of liver diseases and/or infections.
> Non-viral vehicles for use in gene transfer (MC Glick et ai, US) The Children's Hospital of Philadelphia W WO 98/06869, PCT. The invention relates to compositions and methods for transfection of cells, particularly airway epithelial cells, with DNA complexed to polylysine substituted with glycosyl residues. (... ) also relates to methods of treating humans having respiratory disease comprising administering to a human the composition of the invention.
> Improved retroviral vectors for gene therapy (S-Y Kim et ai, KR, US) Viromedica Pacific Ltd and the inventors N" WO 98/12338, PCT. The present invention provides novel, improved retroviral vectors which can be used for gene therapy, more specifically, retroviral vectors which are not only safer, more versatile, and more convenient than any other existing vectors, but they also drive high levels of gene expression and high viral titer. (... 1
CHIMIE-GENIE ENZYMATIOUE Enzvmes > Genes codant pour des iota-carraghenanes et leur utilisation pour la production d'enzymes de biodegradation des carraqhenanes (T Barbeyron et ai, FR) Laboratoires Goemar SA W 9612204, FR. La presente invention a pour objet des genes qui codent pour des glycosyle-hydrolases, ayant un score HCA avec la iota-carraghenase d' Alteromonas fortis qui est superieur ou ega I it 65 %, sur Ie domaine s'etendanr entre les acides arnines 164 et 311 de la sequence proreique SEW IN W2 de ladite iora-carraghenase. > A novel endoglucanase ( ME Bjornvad and P Nielsen, OK) Novo Nordisk AlS and the inventors N" WO 98/08940, PCT. An enzyme prepara tion consisting essentially for and endo-IS-1,4-glucanase (EC3.2.1.4) derived from the bacterial genera Celluibrio mixius or Celluibrio giluus may be produced by recombinant techniques using a cloned DNA sequence encoding the enzyme, e.g. SEQ ID NO: 1. The endo-IS-l ,4-glucanase which has two conserved regions, a first amino acid sequence consisting of 15 amino acid residues having sequence (a) and a second amino acid sequence consisting of 6 amino acid residues having sequence (b) is use-
ful in industrial application conventionally using cellulolytic enzymes.
Fermentation > Procede de production de sophorolipides par fermentation cyclique avec alimentation en esters d'acides gras ou en huiles (R Marchal et ai, FR) Institut francais du petrole N" 9612797, FR.
On decrit un precede de production de sophorolipides par une souche de Candida bombicola dans un milieu contcnant une source d'azote et un substrat. Le precede comprend un premier cycle de fermentation cornportant une etape de croissance de la souche er une crape de production d'un mout de fermentation. ( ... )
ENVIRONNEMENT ENERGIE Bi n p estic ld es > Control of Cyperus spp with a fungal pathogen (J Kadir and R Charudattan, US) University of Florida N" WO 98/08389, PCT. The subject invention concerns a novel bioherbicide and its use to control weeds known as nutsedges (Cyperus spp). The novel fungus, Dactylaria higginsii (Luttrell) M.B. Ellis is pathogenic to purple nutsedge, yellow nutsedge, annual sedge, globe sedge, rice flatsedge, and Cyperus brevi[olius. These sedges cause major losses in different crops and turf. Accordingly, the fungus of the subject invention is an important advance in the control of these noxious weeds. > Insecticidal peptides from Segestria sp spider venom (JH Johnson et ai, US) NPS Pharmaceuticals Inc and the inventors W WO 98/09522, PCT. This invention relates to insecticidally effective peptides isolated from the spider, Segestria sp, characterized by their paralytic effect on insect pests and low mammalian toxicity. BIOFUTUR 180 • Juillet-aoOt 199847
Maladie neurodegenerative > Compositions and methods for treatment of neurological disorders and neurodegenerative diseases (RK Lee and RJ Wurtman, US) Massachusetts Institute of Technology N" WO 98/09523, PCT. It has been discovered that the stimulation of IS-adrenergic receptors, which activate cAMP formation, give rise to increase APP and GFAP synthesis in astrocytes. Hence, the in vitro or in uiuo exposure of neuronal cells to certain compositions comprising IS-adrenergic receptor ligands or agonists, including eg, norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. (...) > Neurological disease
model ( PH van der Putten, CH) Novartis AG and the inventor N° WO 98/11242, PCT. There is provided the use of a metabotropic glutamate receptor mGluR7 agonist for the facilitation of neurotransmitter release from a nerve ending and the treatment of neurological conditions, including epilepsy. Moreover, the invention provides transgenic knockout non-human mammals lacking the mGluR7 gene, suitable for studying mGluR 7 and modulators thereof as well as epilepsy.
Therapies genique
et cellulaire
> Human satelite microchromosomes as vectors for gene therapy (J Xia, CN) Human Medical University N" 838526, EP.
The present invention provides novel eukaryotic expression vectors which can accommodate large polynucleotides, such as polynucleotides encoding genes. The vectors of this invention can be stably maintained and autonomously replicated as extrachromosomal elements in eukaryotic cells, particulary, mammalian, and more particularly human, for use in somatic gene rhera py. (... )
Systeme de delivrance > Compositions and me-
thods for delivery of nucleic acids to hepatocytes (OLJarvis and R Landford, US) The Texas A and M University System and the inventors N" WO 98/06855, PCT. Disclosed are recombinant baculoviruses that are used to deliver hepatocyte expressable nucleic acid constructs specifically to heparocyres. Also provided are a variety of recombinant baculovi;us vectors which comprise at least one oligosaccharide processing enzyme gene and a hepatocyte expressible nucleic acid segment. The invention also provides methods of using the expression systems and recombinant baculoviruses, particularly in the treatment of liver diseases and/or infections.
> Non-viral vehicles for use in gene transfer (MC Glick et ai, US) The Children's Hospital of Philadelphia W WO 98/06869, PCT. The invention relates to compositions and methods for transfection of cells, particularly airway epithelial cells, with DNA complexed to polylysine substituted with glycosyl residues. (... ) also relates to methods of treating humans having respiratory disease comprising administering to a human the composition of the invention.
> Improved retroviral vectors for gene therapy (S-Y Kim et ai, KR, US) Viromedica Pacific Ltd and the inventors N" WO 98/12338, PCT. The present invention provides novel, improved retroviral vectors which can be used for gene therapy, more specifically, retroviral vectors which are not only safer, more versatile, and more convenient than any other existing vectors, but they also drive high levels of gene expression and high viral titer. (... 1
CHIMIE-GENIE ENZYMATIOUE Enzvmes > Genes codant pour des iota-carraghenanes et leur utilisation pour la production d'enzymes de biodegradation des carraqhenanes (T Barbeyron et ai, FR) Laboratoires Goemar SA W 9612204, FR. La presente invention a pour objet des genes qui codent pour des glycosyle-hydrolases, ayant un score HCA avec la iota-carraghenase d' Alteromonas fortis qui est superieur ou ega I it 65 %, sur Ie domaine s'etendanr entre les acides arnines 164 et 311 de la sequence proreique SEW IN W2 de ladite iora-carraghenase. > A novel endoglucanase ( ME Bjornvad and P Nielsen, OK) Novo Nordisk AlS and the inventors N" WO 98/08940, PCT. An enzyme prepara tion consisting essentially for and endo-IS-1,4-glucanase (EC3.2.1.4) derived from the bacterial genera Celluibrio mixius or Celluibrio giluus may be produced by recombinant techniques using a cloned DNA sequence encoding the enzyme, e.g. SEQ ID NO: 1. The endo-IS-l ,4-glucanase which has two conserved regions, a first amino acid sequence consisting of 15 amino acid residues having sequence (a) and a second amino acid sequence consisting of 6 amino acid residues having sequence (b) is use-
ful in industrial application conventionally using cellulolytic enzymes.
Fermentation > Procede de production de sophorolipides par fermentation cyclique avec alimentation en esters d'acides gras ou en huiles (R Marchal et ai, FR) Institut francais du petrole N" 9612797, FR.
On decrit un precede de production de sophorolipides par une souche de Candida bombicola dans un milieu contcnant une source d'azote et un substrat. Le precede comprend un premier cycle de fermentation cornportant une etape de croissance de la souche er une crape de production d'un mout de fermentation. ( ... )
ENVIRONNEMENT ENERGIE Bi n p estic ld es > Control of Cyperus spp with a fungal pathogen (J Kadir and R Charudattan, US) University of Florida N" WO 98/08389, PCT. The subject invention concerns a novel bioherbicide and its use to control weeds known as nutsedges (Cyperus spp). The novel fungus, Dactylaria higginsii (Luttrell) M.B. Ellis is pathogenic to purple nutsedge, yellow nutsedge, annual sedge, globe sedge, rice flatsedge, and Cyperus brevi[olius. These sedges cause major losses in different crops and turf. Accordingly, the fungus of the subject invention is an important advance in the control of these noxious weeds. > Insecticidal peptides from Segestria sp spider venom (JH Johnson et ai, US) NPS Pharmaceuticals Inc and the inventors W WO 98/09522, PCT. This invention relates to insecticidally effective peptides isolated from the spider, Segestria sp, characterized by their paralytic effect on insect pests and low mammalian toxicity. BIOFUTUR 180 • Juillet-aoOt 199847